A carregar...

Minimal residual disease in acute myelogenous leukemia

Treatment of acute myelogenous leukemia (AML) over the past four decades remains mostly unchanged and the prognosis for the majority of patients remains poor. Most of the significant advances that have been observed are in defining cytogenetic abnormalities, as well as the genetic and epigenetic pro...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Lab Hematol
Main Authors: Cruz, N. M., Mencia-Trinchant, N., Hassane, D. C., Guzman, M. L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5652069/
https://ncbi.nlm.nih.gov/pubmed/28447422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ijlh.12670
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!